Innate immunity and alcoholic liver disease

Digestive Diseases

Volumn 30, Issue SUPPL. 1, 2012, Pages 55-60

  Szabo, Gyongyi ^a   Petrasek, Jan ^a   Bala, Shashi ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

IL 1; Inflammation; MicroRNA; TNF ; Toll like receptor

Indexed keywords

CORTICOSTEROID; CRYOPYRIN; INFLAMMASOME; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 155; PENTOXIFYLLINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADAPTIVE IMMUNITY; ALCOHOL LIVER DISEASE; ALCOHOLIC FATTY LIVER; ARTICLE; CELL INTERACTION; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; FATTY LIVER; HEPATITIS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL DAMAGE; LIVER PARENCHYMA; LYMPHOCYTE ACTIVATION; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERLEUKIN-1; KUPFFER CELLS; LIVER DISEASES, ALCOHOLIC; MICRORNAS;

EID: 84867730642     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341126     Document Type: Article

References (54)

1. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J: Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009; 373: 2223-2233.
2. Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, Sandler RS: The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128-2138. (Pubitemid 44337640)
3. Mandrekar P, Szabo G: Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009; 50: 1258-1266.
4. Kawai T, Akira S: TLR signaling. Cell Death Differ 2006; 13: 816-825.
5. O'Neill LA, Sheedy FJ, McCoy CE: Micro-RNAs: The fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11: 163-175.
6. Martinon F, Tschopp J: Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007; 14: 10-22. (Pubitemid 44911890)
7. Szabo G, Mandrekar P, Petrasek J, Catalano D: The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res 2011; 35: 782-786.
8. Dinarello CA: Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732.
9. Adachi M, Brenner DA: Clinical syndromes of alcoholic liver disease. Dig Dis 2005; 23: 255-263. (Pubitemid 43325925)
10. Szabo G, Mandrekar P: A recent perspective on alcohol, immunity, and host defense. Alcohol Clin Exp Res 2009; 33: 220-232.
11. Wu D, Cederbaum AI: Oxidative stress and alcoholic liver disease. Semin Liver Dis 2009; 29: 141-154.
12. Hoek JB, Pastorino JG: Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002; 27: 63-68. (Pubitemid 34626486)
13. Nath B, Szabo G: Alcohol-induced modulation of signaling pathways in liver parenchymal and nonparenchymal cells: Implications for immunity. Semin Liver Dis 2009; 29: 166-177.
14. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG: Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994; 20: 453-460. (Pubitemid 24233374)
15. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108: 218-224.
16. Nanji AA, Khettry U, Sadrzadeh SM: Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994; 205: 243-247. (Pubitemid 24108319)
17. Koop DR, Klopfenstein B, Iimuro Y, Thurman RG: Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1. Mol Pharmacol 1997; 51: 944-950. (Pubitemid 27249127)
18. Thakur V, McMullen MR, Pritchard MT, Nagy LE: Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol 2007; 22(suppl 1):S53-S56. (Pubitemid 46848991)
19. Bode C, Bode JC: Activation of the innate immune system and alcoholic liver disease: Effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 2005; 29: 166S-171S. (Pubitemid 43194346)
20. Szabo G, Bala S: Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-1329.
21. Keshavarzian A, Farhadi A, Forsyth CB, Rangan J, Jakate S, Shaikh M, Banan A, Fields JZ: Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol 2009; 50: 538-547.
22. Rao RK: Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol 2008; 447: 171-183.
23. Petrasek J, Mandrekar P, Szabo G: Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract 2010; 2010: 710381.
24. Enomoto N, Schemmer P, Ikejima K, Takei Y, Sato N, Brenner DA, Thurman RG: Longterm alcohol exposure changes sensitivity of rat Kupffer cells to lipopolysaccharide. Alcohol Clin Exp Res 2001; 25: 1360-1367. (Pubitemid 32868346)
25. Diehl AM: Effect of ethanol on tumor necrosis factor signaling during liver regeneration. Clin Biochem 1999; 32: 571-578. (Pubitemid 30007768)
26. Diehl AM: Cytokines and the molecular mechanisms of alcoholic liver disease. Alcohol Clin Exp Res 1999; 23: 1419-1424. (Pubitemid 29468436)
27. McClain C, Hill D, Schmidt J, Diehl AM: Cytokines and alcoholic liver disease. Semin Liver Dis 1993; 13: 170-182. (Pubitemid 23183172)
28. Thurman RG: II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 1998; 275:G605-G611.
29. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG: Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530-1537. (Pubitemid 27520019)
30. McClain CJ, Barve S, Barve S, Deaciuc I, Hill DB: Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res 1998; 22: 248S-252S. (Pubitemid 28396895)
31. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R: Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425.
32. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broet P, Emilie D, Foie-Alcool group of the Association Francaise pour l'Etude du Foie: A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397. (Pubitemid 38569061)
33. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebocontrolled trial. Gastroenterology 2000; 119: 1637-1648. (Pubitemid 32198689)
34. O'Shea RS, Dasarathy S, McCullough AJ: Alcoholic liver disease. Am J Gastroenterol 2010; 105: 14-32, quiz 33.
35. Hill DB, D'Souza NB, Lee EY, Burikhanov R, Deaciuc IV, de Villiers WJ: A role for interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res 2002; 26: 74-82. (Pubitemid 34093514)
36. Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G: The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol 2009; 183: 1320-1327.
37. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13: 267-276.
38. Miller AM, Horiguchi N, Jeong WI, Radaeva S, Gao B: Molecular mechanisms of alcoholic liver disease: Innate immunity and cytokines. Alcohol Clin Exp Res 2011; 35: 787-793.
39. Schroder K, Tschopp J: The inflammasomes. Cell 2010; 140: 821-832.
40. Ambros V: The functions of animal micro-RNAs. Nature 2004; 431: 350-355.
41. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233.
42. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089.
43. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486. (Pubitemid 44267285)
44. Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, Szabo G: Up-regulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011; 286: 1436-1444.
45. Faraoni I, Antonetti FR, Cardone J, Bonmassar E: MiR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792: 497-505.
46. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-4407.
47. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
48. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K: The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741.
49. Bala S, Marcos M, Szabo G: Emerging role of microRNAs in liver diseases. World J Gastroenterol 2009; 15: 5633-5640.
50. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM: MiR-122, a mammalian liver-specific micro-RNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1: 106-113.
51. Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, Fei M, Sun S: Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemicalrelated hepatic diseases. Clin Chem 2010; 56: 1830-1838.
52. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M: Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
53. Brown BD, Naldini L: Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet 2009; 10: 578-585.
54. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, Sasso GF, Xirouchakis E, Attilia ML: Acute alcoholic hepatitis. J Clin Gastroenterol 2006; 40: 833-841. (Pubitemid 44506929)